Application | Comment | Organism |
---|---|---|
drug development | silencing CYP17 expression may be a strategy for therapy of hyperandrogenism diseases, and also sets an example for the use of RNAi technology in endocrine diseases | Rattus norvegicus |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Rattus norvegicus | - |
female Sprague-Dawley rats | - |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
ovarian theca-interstitial cell | - |
Rattus norvegicus | - |
Synonyms | Comment | Organism |
---|---|---|
17alpha-hydroxylase/17,20-lyase | - |
Rattus norvegicus |
CYP17 | - |
Rattus norvegicus |
Organism | Comment | Expression |
---|---|---|
Rattus norvegicus | shRNA treatment significantly decreases CYP17 mRNA and protein levels in vitro. Silence efficiency of three constructed lentivirus shRNAs is 65.5%, 73.7% and 77.4%, respectively. Three constructed lentivirus shRNAs also have silencing effects on CYP17 protein expression, and their silence efficiencies are 50%, 50% and 61%, respectively. In vivo, shRNA still has a specific silencing effect on CYP17 | down |
General Information | Comment | Organism |
---|---|---|
malfunction | ovarian androgen biosynthesis can be inhibited by silencing CYP17 expression | Rattus norvegicus |